Biohaven shares Phase II BHV-7000 trial results for major depressive disorder

Biohaven has reported findings from its Phase II proof-of-concept trial of BHV-7000 in adults with major depressive disorder (MDD), assessing symptom reduction via the Montgomery Åsberg Depression Rating Scale (MADRS) over six weeks. While the study did not meet its primary endpoint versus placebo, trends suggested potential benefits in certain subgroups, particularly participants with more severe baseline depression.

The treatment was generally well tolerated, with adverse events mostly mild or moderate and resolving spontaneously. Headaches occurred in 10.7% of BHV-7000 recipients versus 9.9% on placebo, and nausea in 4.2% versus 5.6%. Central nervous system adverse events were low, consistent with the drug’s lack of GABA activity.

Biohaven plans further analyses and will present updates—including extracellular degrader programmes and ongoing BHV-7000 trials—at the J.P. Morgan Healthcare Conference in January 2026.

29-12-2025